

1 **ACCEPTED MANUSCRIPT**

2

3 **EFFECTIVENESS OF DIFFERENT METHODS FOR PREVENTING *Aeromonas hydrophila***  
4 **AND *Pseudomonas fluorescens* INFECTION IN TILAPIA**

5

6 **Hardi EH, Saptiani G, Kusuma IW, Nugroho RA<sup>3</sup>, Suwinarti W, Anjani R, Aziza**

7

8 **DOI: -**

9

10 **To appear in : BIOTROPIA Issue**

11

12 **Received date : 19 September 2018**

13 **Accepted date : 08 July 2019**

14

15 **This manuscript has been accepted for publication in BIOTROPIA journal. It is unedited, thus,**  
16 **it will undergo the final copyediting and proofreading process before being published in its final**  
17 **form.**

ACCEPTED MANUSCRIPT

# EFFECTIVENESS OF DIFFERENT METHODS FOR PREVENTING

## *Aeromonas hydrophila* AND *Pseudomonas fluorescens* INFECTION IN TILAPIA

Esti Handayani Hardi<sup>1\*</sup>, Gina Saptiani<sup>1</sup>, Irawan Wijaya Kusuma<sup>2</sup>, Rudi Agung Nugroho<sup>3</sup>,  
Wiwin Suwinarti<sup>2</sup>, Ryan Anjani<sup>1</sup> and Aziza<sup>1</sup>

<sup>1</sup>Department of Aquaculture, Faculty of Fisheries and Marine Science, Universitas Mulawarman,  
Samarinda 75123, Indonesia

<sup>2</sup>Faculty of Forestry, Universitas Mulawarman, Samarinda 75123, Indonesia

<sup>3</sup>Department of Biology, Faculty of Mathematics and Natural Sciences, Universitas Mulawarman,  
Samarinda 75123, Indonesia

\*Corresponding author, e-mail: estieriyadi2011@gmail.com

Running title: Method for preventing *A. hydrophila* and *P. fluorescens* infection in Tilapia

### ABSTRACT

This research evaluated a method involving provision of a concoction of *Boesenbergia pandurata*, *Solanum ferox* dan *Zingiber zerumbet* extracts for pathogen prevention in tilapia. The concentration of each extract was 600 ppm of *Boesenbergia pandurata*/BP, 900 ppm of *Solanum ferox*/SF and 200 ppm of *Zingiber zerumbet*/ZZ. The examination was performed by issuing two combinations of extracts (SF:BP, SF:ZZ) against *Aeromonas hydrophila* and *Pseudomonas fluorescens* ( $10^5$  CFU $mL^{-1}$ ). Preventive trials were carried out by providing a concoction of extracts through intraperitoneal injection (0.1 mL/fish) in tilapia (15±2 g) and the immersion method was performed by bathing the fish in the extracts for 20 minutes, with pathogen challenging during the following 24 h being carried out. The composition of the used extract was by SF60:ZZ40; SF50:ZZ50; BP90:SF10; BP50:SF50; and fish without being given the extract. Haematology and immunology parameters were observed at the 4<sup>th</sup> week after challenges with pathogenic bacteria. The number of white blood cells (WBCs) increased significantly ( $P < 0.05$ ) compared to controls without extract, with a similar increase observed for red blood cell (RBCs), but hematocrit (Ht) and hemoglobin (Hb) values did not significantly increase compared to control. Phagocytic index, respiratory burst and lysozyme activities also experienced a significant increase in fish fed with combined extracts compared to controls. The numbers of pathogenic bacteria in the body of the fish given extract were also lower than the control and significantly different at the 4<sup>th</sup> week. The results of this study showed that the administration of a combined extract of SF50: ZZ50 and BP90: SF10 provided the best protection as indicated by relative survival percent (RPS) of 100% after being tested challenged with *A. hydrophila* and *P. fluorescent* by. This study indicates that providing combined extracts by injection and immersion in the ratio of SF50:ZZ50 has a positive effect in increasing the non-specific immune system of tilapia and increasing protection against bacterial infections.

**Keywords:** *Aeromonas hydrophila*, concoction, imunomodulator, *Pseudomonas fluorescens*

### INTRODUCTION

The increase of global fish farming has been occurring rapidly, with increased biomass production, species diversification, geographical expansion and enlarging methods to fulfill the protein needs of fish. The increase has continually faced challenges due to associated diseases and health problems of aquacultural animals. Another triggering factor is climate change and the development of affecting aquaculture technologies in the balance or imbalance of interactions

64 between pathogens, hosts and the environment. Almost every year, new aquacultural pathogens are  
65 being isolated and novel diseases continue to be identified in various areas of cultivation and many  
66 species in these areas (Rodger 2018).

67 *Aeromonas hydrophila* and *Pseudomonas fluorescens* are two pathogenic bacteria occurring  
68 throughout the year, with a mortality rate of 60–80% (Hardi *et al.* 2012, 2016, 2017). *Aeromonas*  
69 causes loss and destruction of the aquaculture industry around the world (Monette *et al.* 2006). Fish  
70 infected with these bacteria include (Janda & Abbott 2010) tilapia *Oreochromis niloticus* (Hardi *et*  
71 *al.* 2012), *Cyprinus carpio* (Sioutas *et al.* 1991; Monette *et al.* 2006), *Clarias gariepinus* (Chowdhury  
72 1998) and indian major carps (Karunasagar *et al.* 1991). Combined bacterial infections are typically  
73 found in nature with heavier symptoms than in single bacterial infections. Combined infection of *A.*  
74 *hydrophila* and *P. fluorescens* leads to stressed fish, exoptalmia, ulcers and watery organs in the bile  
75 gland rupture. Likewise, combined infections of *Streptococcus agalactiae* and *A. hydrophila* cause  
76 tilapia and goldfish to die more rapidly than single bacterial infections (Sugiani *et al.* 2012; Sumiati  
77 *et al.* 2015).

78 Many of the fish diseases or pathogens do not yet have suitable preventative or treatment  
79 options. For example, the use of vaccines, immunostimulants, antibacterials, and environmental  
80 management to minimize epidemics. The fish vaccines are particularly varied for freshwater fish  
81 because many strains infect these bacteria. The availability of commercial immunostimulants  
82 deriving from natural ingredients is still limited due to the low level of immunomodulatory  
83 components contained in natural compounds (Pridgeon & Klesius 2012). Some beneficial  
84 immunomodulatory components in plants for fish include levamisole and saponins (Findlay &  
85 Munday 2000) being able to increase the non-specific immune systems activity (phagocytosis  
86 activation of leucocyte and WBC) (Bricknell *et al.* 2005). The single extract of *B. pandurata* and *Z.*  
87 *zerumbet* plants from East Kalimantan have antibacterial activity *in vitro* and *in vivo* against *A.*  
88 *hydrophila* bacteria, while a single extract of *S. ferox* effectively inhibits *P. fluorescens* infection  
89 (Hardi *et al.* 2016a, 2016b). That extract can be used for prevention and treatment of infections of  
90 both bacteria in tilapia (Hardi *et al.* 2017, 2018b).

91 To increase the immunomodulatory activities from plant extracts, several extracts were  
92 combined in application. A concoction of *Curcuma longa*, *Ocimum sanctum* and *Azadirachta indica*  
93 extracts at a ratio of 1:1:1 more effectively inhibits *A. hydrophila* bacteria *in vitro* compared to a  
94 single extract of each plant (Harikrishnan & Balasundaram 2008); the combined treatment of three  
95 extracts can increase the survival rate and inhibitory process due to infection by *A. hydrophila* bacteria  
96 in goldfish (*Carassius auratus*) (Harikrishnan *et al.* 2009). A concoction of *Boesenbergia*  
97 *pandurata*, *Solanum ferox*, and *Zingiber zerumbet* extract at a ratio 1:1:1 in tilapia has an  
98 immunomodulatory effect in tilapia and could increase protection and diseases recovery from *A.*

99 *hydrophila* and *Pseudomonas fluorescens* better than single extract (Hardi *et al.* 2019a). some  
100 research show that *B. pandurata* and *Z. zerumbet* extracts contains alkaloids, flavonoids,  
101 carbohydrates, and steroids (Hardi *et al.*, 2016a). While the ekstrak of *S. ferox* has higher levels of  
102 alkaloids that play an important role as antibacterial properties (Hardi *et al.*, 2016a and Huang *et al.*  
103 2008).

104 A concoction of three extracts of *B. pandurata*, *Z. zerumbet* and *S. ferox* had *in vitro*  
105 antibacterial activity against *A. hydrophila* and *P. fluerescens* both in single and combined use (Hardi  
106 *et al.* 2018a; 2018b). This paper will discuss the effectiveness of these three extracts to prevent  
107 infection from *A. hydrophila* and *P. fluerescens* bacteria in tilapia using injection and immersion  
108 methods.

109

110

## MATERIALS AND METHODS

### 111 **Fish and Bacteria**

112 Tilapia used in this research were of size  $15 \pm 2$  g, taken from the village of Teluk Dalam,  
113 Tenggarong Seberang Kutai Kartanegara. The tilapia fish had been kept at the laboratory for two  
114 weeks prior to use. The aquarium used for treatment was 60 x 40 x 30 cm, containing 60 L of water,  
115 50% of which was changed every two days to remove remaining fish fesses and feed.

116 The bacteria used for the challenge trial were combination of *A. hydrophila* (EA-01) and *P.*  
117 *fluerescens* (EP-01) with ratio 1:1, derived from the Aquatic Microbiology laboratory, Faculty of  
118 Fisheries and Marine Sciences, Mulawarman University, Indonesia. Bacterial density was  $10^5$   
119 CFU $mL^{-1}$  each bacteria, with 1 mL/fish being injected intramuscularly.

120

### 121 **Extract Preparation for *B. pandurata*, *Z. zerumbet* and *S. ferox***

122 The rhizomes of plants used in the study were *B. pandurata* and *Z. zerumbet*, and fruit of *S.*  
123 *ferox*. All of them were collected from traditional markets in Samarinda City, East Kalimantan. Plants  
124 were cleaned of dirt, cut into slices, dried in an oven at 40 °C for 48 hours, blended in powder form  
125 and refrigerated at -4 °C until the extraction stage continued. The method for extraction uses ethanol  
126 solution and follows Limsuwan & Voravuthikunchai (2008). The concentrations of each extract were  
127 *B. pandurata* and *Z. zerumbet*, and *S. ferox* respectively 600, 200 and 900 mg $L^{-1}$ . Comparison of  
128 combination of *Z. zerumbet* and *S. ferox* extracts with rasio 40:60 and 50:50 mL. Comparison of *B.*  
129 *pandurata* and *S. ferox* 90:10 mL and 50:50 mL.

130

### 131 **Experiment**

132 Extract was given to tilapia via use of injection and immersion methods to avoid bacterial  
133 infection of *A. hydrophila* and *P. fluerescens*. A preventive experiment was performed by issuing

134 combined extracts through intraperitoneal injection (IP) at a rate of 0.1 mL/fish and waiting for seven  
135 days; on the 8<sup>th</sup> day, fish were challenged with pathogenic bacteria. Regarding the immersion method  
136 for preventing pathogenic bacteria, fish were immersed for 20 minutes with a combination of extracts,  
137 and challenged with the combined bacteria through intramuscular injection (IM) on the 8<sup>th</sup> day. The  
138 experiment was carried out every week after injecting with bacteria until the 4<sup>th</sup> week. In addition,  
139 the applied research treatment comprised nine groups:

140 Group 1 = IP injected fish with combination of 60 ml of *S. ferox* extract, 40 ml of *Z. zerumbet*  
141 extract (SF 60:ZZ 40) and challenge through IM injection with combination of pathogen  
142 bacteria.

143 Group 2 = IP injected fish with combination of 50 ml of *S. ferox* extract and 50 ml of *Z. zerumbet*  
144 extract (SF 50:ZZ 50) and challenged through IM injection with combination of  
145 pathogenic bacteria.

146 Group 3 = IP injected fish with combination of 90 ml of *B. pandurata* extract and 10 ml of *S. ferox*  
147 (BP 90:SF 10) and challenged through IM injection with combination of pathogenic  
148 bacteria.

149 Group 4 = IP injected fish with combination of 50 ml of *B. pandurata* extract and 50 ml of *S. ferox*  
150 extract (BP 50:SF 50) challenged through IM injection with combination of pathogenic  
151 bacteria.

152 Group 5 = Immersion fish with combination of 60 ml of *S. ferox* extract and 40 ml of *Z. zerumbet*  
153 extract (SF 60:ZZ 40) challenged through IM injection with combination of pathogenic  
154 bacteria.

155 Group 6 = Immersion fish with combination of 50 ml of *S. ferox* extract and 50 ml of *Z. zerumbet*  
156 extract (SF 50:ZZ 50) challenged through IM injection with combination of pathogenic  
157 bacteria.

158 Group 7 = Immersion fish with combination of 90 ml of *B. pandurata* extract and 10 ml of *S. ferox*  
159 extract (BP 90:SF 10) challenged through IM injection with combination of pathogenic  
160 bacteria.

161 Group 8 = Immersion fish with combination of 50 mL of *B. pandurata* extract and 50 ml of *S. ferox*  
162 extract (BP 50:SF 50) challenge via IM injection with combination of pathogenic  
163 bacteria.

164 Group 9 = IP injected fish with PBS (phosphat buffer saline) sterile and challenge through IM  
165 injection with combination of pathogen bacteria.

166 Group 10 = Immersion fish with PBS sterile and challenge via IM injection with combination of  
167 pathogenic bacteria.

168 In this research, every group using 10 fish every aquarium and three replication, so 30 fish  
169 using every groups, to evaluate the effective method. Total tilapia were used in this research to  
170 evaluate the extract administration with the different method (IP and immersion) in non-specific  
171 immunity, survival rate (SR), and Relative Percent Survival (RPS) were 300 *Oreochromis niloticus*.

172

### 173 **Hematological Examination**

174 Every week (first, second, third and fourth) during one month after challenging with  
175 pathogenic bacteria, hematological observations were obtained. Before blood was taken, the fish were  
176 anesthetized using 50 mg MS-222 dm<sup>-3</sup>, and blood was obtained through the base of the fish, with 1  
177 ml of injection syringe being washed with anticoagulants (10% tri sodium citrate). Red Blood Cells  
178 (RBC) and White Blood Cells (WBC) parameters were observed using a Neubauer haemocytometer.  
179 Observation of RBC begins by adding blood samples with Hayem's solvent and adding Turk's solvent  
180 for the observation of WBC. Hemoglobin examination involved use of a sahli tube. Hematocrit (Ht  
181 %) was measured using the microcentrifuge method, and the standard solvent employed was tri  
182 sodium citrate. The inserted blood into the micro hematocrit tube was centrifuged at 7,000 g for 10  
183 min. Hematocrit is estimated by calculating the ratio of the column of packed erythrocytes to the total  
184 length of the sample in the capillary tube, measured with a graphic reading device (Blaxhall and  
185 Daisley Methods, 1973).

186

### 187 **Index Phagocytic**

188 Fifty µL of blood was transferred into an eppendorf tube containing 50 µL, mixed of *A.*  
189 *hydrophila* and *P. fluorescens* suspension (the density of each bacteria were 10<sup>5</sup> CFU mL<sup>-1</sup>), and left  
190 for 20 minutes. The preparation of the smear was made on a glass object and dried, fixed with alcohol  
191 (95%) for five minutes, then dried again. The preparation was then coloured by soaking it in Giemsa  
192 dye (10%) for 15 minutes, washed with flowing water and dried. The preparations were then observed  
193 and the number of cells demonstrating phagocytic processes were counted (100 phagocytic cells were  
194 observed), the method according to Anderson and Siwicki (1995). This parameter was observed in  
195 week 4<sup>th</sup> after challenges (IM) with *A. hydrophila* and *P. flourescens*.

196

### 197 **Respiratory Burst**

198 The test of respiratory burst activity involved use of nitro blue tetrazolium (NBT) reagent.  
199 Blood derived from fish (50 µL) was transferred to a microplate, incubated for one hour at 37 ° C,  
200 the supernatant removed; cells were washed with 50 µL of PBS three times, 50 µL of 0.2% NBT was  
201 added and incubated for one hour at 37 ° C. Plates were fixed with 100% methanol (50 µL) for 2–3  
202 minutes, then rinsed with 30% methanol (50 µL) three times and air-dried. Then, 60 µL of KOH and

203 70  $\mu$ L of DMSO were added, with the optical density then checked using an ELISA Reader at a  
204 wavelength of 540 nm the parameter analyzed by Secombes and Fletcher (1992) method. Like a  
205 index phagocytosis, this parameter was observed in week 4th after challenges (IM) with *A. hydrophila*  
206 and *P. fluorescens*.

207

### 208 ***Lysozyme Activity***

209 Moistened injection syringes with anticoagulants were prepared, with the blood of the fish  
210 from the caudal vein taken. Blood was stored at room temperature for two hours and then maintained  
211 at 4 °C for 24 hours. Blood was centrifuged at 5,000 rpm for three minutes, with the separated clear  
212 liquid (serum) then being removed. The test for lysozyme activity was performed according to the  
213 method of Lygren *et al.* (1999) — 10  $\mu$ l of serum sample was placed into a micro titer plate and then  
214 190  $\mu$ l of lysodeikticus *Micrococcus* suspension added (Sigma Aldrich Chemical) (0.2 mg of  
215 lysodeikticus *Micrococcus* / mL PBS (pH 7.4)) shaking slowly at constant room temperature. After  
216 90 minutes of incubation, a micro titer ELISA plate reader at a wavelength of 520 nm (Lie *et al.* 1989)  
217 was used to take readings.

218 Relative lysozyme activities (units) were calculated as follows: 1 Unit = 0.001 decrease in  
219 absorbance/minute. If the calculation of lysozyme activity is absolutely necessary, it can use a  
220 standard solution of chicken egg white with several concentrations in order to ensure that the standard  
221 measurement procedure curve is the same. The parameter analyzed according to Lygren *et al.* (1999)  
222 and observed in week 4th after challenges (IM) with *A. hydrophila* and *P. fluorescens*.

223

### 224 **Total Bacteria in Fish Bodies using TPC**

225 Calculation of total bacteria in the fish body was carried out to determine the antibacterial  
226 activity due to injection with combined extracts of *A. hydrophila* and *P. fluorescens*. The  
227 measurement of total bacteria using the TPC method was performed by counting the number of  
228 bacterial colonies in the fish's organs using  $10^{-2}$  to  $10^{-6}$  dilutions. The initial bacterial concentration  
229 was calculated using plates containing 30–300 colonies.

230 As a first step, petri cups, test tubes and pipettes were sterilized using dried sterilization (180  
231 °C for two hours) prior to use. PCA solid media were used as a growth substrate, wet-sterilized in an  
232 autoclave (121 °C for 15 minutes, 1 atm). Samples of ten grams of fish (thymus, kidney, spleen, and  
233 liver), were mashed first, then dissolved in 100 ml of sterile diluent solvent to obtain a  $10^{-1}$  dilution.  
234 One ml was then taken, and put in sample tubes containing 9 ml of sterile distilled water ( $10^{-2}$ ) until  
235 a dilution of  $10^{-6}$  was achieved. A total of 1 ml of each tube was transferred into a sterile petri cup  
236 and approximately 15 mL of PCA media was poured evenly; the petri dish was incubated for 48 hours  
237 at 30 °C (the petri dish was placed upside down in the incubator) and growing colonies then counted,

238 based of Mailoa et al. (2017) method. At the end of the incubation period, select all of the petri plates  
239 containing between 30 and 300 colonies. Plates with more than 300 colonies cannot be counted and  
240 are designated too many to count (TMTC). Plates with fewer than 30 colonies are designated too few  
241 to count (TFTC). Count the colonies on each plate and a quebec colony counter should be used. This  
242 parameter was observed in week 4th after chalanges (IM) with *A. hydrophila* and *P. flourescens*.

$$\text{number of colonies (CFU)/mL} = \frac{\sum \text{Colony of bacteria}}{\text{dilution} \times \text{amount plated}}$$

### 246 **Protection Level for Pathogens**

247 To determine the effectiveness of combined extracts to prevent *A. hydrophila* and *P.*  
248 *flourescens* infection, the challenge-tested fish were counted with respect to number survival rate (SR)  
249 and the protection level (RPS) was calculated on week 4<sup>th</sup> after IM infectio, and observations using  
250 the Amend (1981) and Ellis formula (1988).

$$\text{SR} = \frac{(\text{alive fish at the end of the treatment})}{(\text{alive fish at the beginning of the treatment})} \times 100$$

$$\text{RPS} = 1 - \frac{(\text{percent mortality in treated group})}{\text{Percent mortality in control group}} \times 100$$

### 254 **Statistics Data analysis**

255 The data obtained were analyzed statistically using SPSS 16.0 to determine the effect of extract  
256 treatment on observation parameters.

## 258 **RESULTS AND DISCUSSION**

### 259 **Hematology**

260 The total tilapia WBCs to prevent bacterial infection of *A. hydrophila* and *P. fluorosence*  
261 using the immersion method (Table 1) significantly increased ( $P < 0.05$ ) starting from the 2<sup>nd</sup> week to  
262 the 4<sup>th</sup> week after being given the combined extract (Group 5-Group 8) compared with controls  
263 (Group 10) without extract. The highest increase was experienced by tilapia given the combined  
264 extract of *B. pandurata* and *S. ferox* at a 50:50 of ratio (Group 6) from the 2<sup>nd</sup> week to the 4<sup>th</sup> week  
265 after bacterial infection by IM. Likewise, total RBC counts (Group 5-Group 8) significantly increased  
266 with control fish ( $P < 0.05$ ) since the second week of treatment, while hematocrit levels (Group 5-  
267 Group 8) significantly increased ( $P < 0.05$ ) in weeks 3 and 4. Post-treatment tilapia hemoglobin levels  
268 in Group 5-Group 8 were increased but not significantly different to control/Group 10 ( $P < 0.05$ ).

269



270  
271

Table 1. Haematology of tilapia in preventive method using a combination of extracts to bacterial infection of *A. hydrophila* and *P. fluorescens* through immersion methods

Variable	Groups	Extracts	Weeks			
			1	2	3	4
WBC ( $10^4$ cell/mm <sup>3</sup> )	5	SF 60 : ZZ 40	1.5±0.1 <sup>a</sup>	1.4±0.1 <sup>a</sup>	1.6±0.1 <sup>a</sup>	2.0±0.2 <sup>b</sup>
	6	SF 50 : ZZ 50	2.0±0.2 <sup>b</sup>	3.2±0.1 <sup>b</sup>	3.8±0.2 <sup>c</sup>	7.6±0.2 <sup>d</sup>
	7	BP 90 : SF 10	1.7±0.2 <sup>b</sup>	1.7±0.5 <sup>b</sup>	2.0±0.1 <sup>b</sup>	2.0±0.1 <sup>b</sup>
	8	BP 50 : SF 50	1.9±0.5 <sup>b</sup>	1.7±0.5 <sup>b</sup>	1.8±0.2 <sup>b</sup>	2.0±0.1 <sup>b</sup>
	10	No extract	1.3±0.3 <sup>a</sup>	1.3±0.2 <sup>a</sup>	1.3±0.2 <sup>a</sup>	1.3±0.1 <sup>a</sup>
RBC ( $10^6$ cell/mm <sup>3</sup> )	5	SF 60 : ZZ 40	5.9±0.1 <sup>b</sup>	5.0±0.1 <sup>b</sup>	4.0±0.2	5.3±0.1
	6	SF 50 : ZZ 50	5.9±0.1 <sup>b</sup>	7.0±0.2 <sup>c</sup>	7.8±0.1 <sup>c</sup>	6.9±0.2 <sup>c</sup>
	7	BP 90 : SF 10	5.1±0.2 <sup>b</sup>	6.0±0.1 <sup>c</sup>	6.2±0.1 <sup>c</sup>	4.4±0.2 <sup>b</sup>
	8	BP 50 : SF 50	5.2±0.1 <sup>b</sup>	6.0±0.2 <sup>c</sup>	6.0±0.1 <sup>c</sup>	6.7±0.1 <sup>c</sup>
	10	No extract	2.0±0.3 <sup>a</sup>	2.0±0.1 <sup>a</sup>	2.7±0.2 <sup>a</sup>	2.4±0.1 <sup>a</sup>
Hematokrit (%)	5	SF 60 : ZZ 40	20±0.1 <sup>a</sup>	23±0.1 <sup>a</sup>	27±0.1 <sup>b</sup>	30±0.1 <sup>b</sup>
	6	SF 50 : ZZ 50	20.5±0.5 <sup>a</sup>	23±0.2 <sup>a</sup>	28±0.1 <sup>b</sup>	30±0.2 <sup>b</sup>
	7	BP 90 : SF 10	22.5±0.5 <sup>a</sup>	23±0.2 <sup>a</sup>	30±0.1 <sup>b</sup>	31±0.2 <sup>b</sup>
	8	BP 50 : SF 50	25±0.2 <sup>a</sup>	23±0.2 <sup>a</sup>	27±0.2 <sup>b</sup>	30±0.2 <sup>b</sup>
	10	No extract	20±0.2 <sup>a</sup>	15±0.3 <sup>a</sup>	18±0.1 <sup>a</sup>	15±0.2 <sup>a</sup>
Hemoglobin (g%)	5	SF 60 : ZZ 40	8±0.1 <sup>a</sup>	8±0.3 <sup>a</sup>	8±0.1 <sup>a</sup>	8±0.1 <sup>a</sup>
	6	SF 50 : ZZ 50	10±0.2 <sup>a</sup>	8±0.3 <sup>a</sup>	10±0.2 <sup>a</sup>	8±0.1 <sup>a</sup>
	7	BP 90 : SF 10	8±0.1 <sup>a</sup>	8±0.2 <sup>a</sup>	10±0.2 <sup>a</sup>	10±0.1 <sup>a</sup>
	8	BP 50 : SF 50	8±0.1 <sup>a</sup>	8±0.2 <sup>a</sup>	8±0.2 <sup>a</sup>	10±0.1 <sup>a</sup>
	10	No extract	6.3±0.5 <sup>a</sup>	8±0.1 <sup>a</sup>	6±0.2 <sup>a</sup>	6±0.2 <sup>a</sup>

272 Notes: Values (means ± SD) with different superscript in a row show significant differences ( $P <$   
273 0.05).  
274

275 Preventive test through the injection (IP) method (Table 2) showed that WBC had the highest  
276 increase in tilapia using the treatment ratio of SF 50: ZZ 50 (Group 2). The increase was significantly  
277 different with the control/Group 9 ( $P < 0.05$ ) in Group 1-Group 4 treatment by IP from 1<sup>st</sup> to 4<sup>th</sup> week  
278 of observations. A similar result was showed RBC and hematocrit, with results for fish given extracts  
279 being significantly different ( $P < 0.05$ ) to control. Only fish hemoglobin (Group 1-Group 4) was not  
280 significantly different with the fish control in terms of prevention of bacterial infections via the IP  
281 method.

282

283 Table 2. Haematology of tilapia in preventive testing using a combined extract against bacterial  
284 infection of *A. hydrophila* and *P. fluorescens* through IP method


Variable	Groups	Extracts	Weeks			
			1	2	3	4
WBC ( $10^4$ cell/mm <sup>3</sup> )	1	SF 60 : ZZ 40	1.7±0.5 <sup>a</sup>	2.2±0.15 <sup>a</sup>	1.8±0.2 <sup>a</sup>	1.8±0.5 <sup>a</sup>
	2	SF 50 : ZZ 50	3.4±0.3 <sup>b</sup>	4.3±0.2 <sup>b</sup>	4.0±0.1 <sup>b</sup>	4.9±0.2 <sup>c</sup>
	3	BP 90 : SF 10	2.0±0.15 <sup>a</sup>	2.7±0.2 <sup>a</sup>	2.4±0.1 <sup>a</sup>	2.4±0.3 <sup>a</sup>
	4	BP 50 : SF 50	2.4±0.25 <sup>a</sup>	2.8±0.3 <sup>a</sup>	2.0±0.2 <sup>a</sup>	2.5±0.1 <sup>a</sup>
	9	No extract	1.5±0.1 <sup>a</sup>	1.3±0.5 <sup>a</sup>	1.3±0.3 <sup>a</sup>	1.3±0.1 <sup>a</sup>

RBC ( $10^6$ cell/mm <sup>3</sup> )	1	SF 60 : ZZ 40	7.4±0.15 <sup>d</sup>	6.8±0.25 <sup>c</sup>	5.9±0.2 <sup>c</sup>	6.0±0.5 <sup>c</sup>
	2	SF 50 : ZZ 50	7.9±0.2 <sup>d</sup>	7.7±0.3 <sup>d</sup>	6.0±0.1 <sup>c</sup>	6.0±0.2 <sup>c</sup>
	3	BP 90 : SF 10	5.5±0.1 <sup>b</sup>	6.6±0.1 <sup>c</sup>	5.0±0.1 <sup>b</sup>	5.4±0.2 <sup>b</sup>
	4	BP 50 : SF 50	5.8±0.1 <sup>b</sup>	5.8±0.1 <sup>b</sup>	7.7±0.1 <sup>c</sup>	7.0±0.1 <sup>c</sup>
	9	No extract	2.4±0.2 <sup>a</sup>	2.6±0.2 <sup>a</sup>	2.7±0.2 <sup>a</sup>	2.4±0.1 <sup>a</sup>
Hematokrit (%)	1	SF 60 : ZZ 40	31±0.5 <sup>b</sup>	25±0.1 <sup>a</sup>	22±0.1 <sup>a</sup>	22±0.1 <sup>a</sup>
	2	SF 50 : ZZ 50	22.2±0.15 <sup>a</sup>	25±0.2 <sup>a</sup>	20±0.2 <sup>a</sup>	22±0.1 <sup>a</sup>
	3	BP 90 : SF 10	25±0.1 <sup>a</sup>	25±0.1 <sup>a</sup>	30±0.2 <sup>a</sup>	21.5±0.1 <sup>a</sup>
	4	BP 50 : SF 50	25±0.2 <sup>a</sup>	25±0.1 <sup>a</sup>	25±0.1 <sup>a</sup>	21±0.2 <sup>a</sup>
	9	No extract	20±0.1 <sup>a</sup>	15±0.2 <sup>a</sup>	14±0.1 <sup>a</sup>	15±0.1 <sup>a</sup>
Hemaglobin (g%)	1	SF 60 : ZZ 40	10±0.2 <sup>a</sup>	10±0.1 <sup>a</sup>	8±0.2 <sup>a</sup>	9±0.2 <sup>a</sup>
	2	SF 50 : ZZ 50	10±0.2 <sup>a</sup>	10±0.1 <sup>a</sup>	8±0.2 <sup>a</sup>	9±0.1 <sup>a</sup>
	3	BP 90 : SF 10	10±0.2 <sup>a</sup>	10±0.1 <sup>a</sup>	8±0.1 <sup>a</sup>	8±0.1 <sup>a</sup>
	4	BP 50 : SF 50	10±0.2 <sup>a</sup>	10±0.1 <sup>a</sup>	8±0.1 <sup>a</sup>	8±0.2 <sup>a</sup>
	9	No extract	6.3±0.2 <sup>a</sup>	7±0.1 <sup>a</sup>	5±0.1 <sup>a</sup>	4±0.1 <sup>a</sup>

285 Notes: Values (means ±SD) with different superscript in a row show significant differences ( $P <$   
 286 0.05).  
 287

### 288 *Index Phagocytic*

289 The fish given the combined extract of SF 50: ZZ 50 (Group 2) through the injection method  
 290 (IP) showed the highest index phagocytic improvement compared to the other treatments (Group 1,  
 291 3,4,5,6,7,8) at the 4th week after the challenge test and were significantly different to the  
 292 controls/Group 9 ( $P < 0.05$ ). Likewise, with the immersion method, prevention from bacterial  
 293 infections of *A. hydrophila* and *P. fluorescens* with a combined extract of SF 50: ZZ 50 (Group 6)  
 294 showed the highest increase of index phagocytic in the 4<sup>th</sup> week after the challenge (IM) test. The  
 295 entire treatment of the extract combination was increased and significantly different from the control  
 296 ( $P < 0.05$ ). All combination of extract (Group 1- Group 8) were increased in index phagocytic and  
 297 significantly to the controls in the 4<sup>th</sup> week after the challenge test (Figure 1).  
 298



299


300 Figure 1. Index phagocytic of tilapia on challenge test using combined extract to bacterial infection  
301 of *A. hydrophila* and *P. fluorescense* through injection and immersion methods.  
302 Different superscript in a row show significant differences ( $P < 0.05$ ).

303

### 304 Respiratory Burst

305 Respiratory burst activity of tilapia given a combination of extracts increased during the 4<sup>th</sup>  
306 week either through injection or immersion methods (Figure 2.). A significant increase compared to  
307 the control group occurred in all given extracts with different combinations. However, only the ratio  
308 of SF 50:ZZ 50 by IP method (Group 2) was significantly different ( $P < 0.05$ ) from the combination  
309 of other extracts and to the controls (Group 9).

310



311


312 Figure 2. Respiratory burst activity of tilapia on preventive methods by using a combination of  
313 extracts to bacterial infection of *A. hydrophila* and *P. fluorescense* through injection and  
314 immersion method

315

### 316 Lysozyme Activity

317 The activity of tilapia lysozyme given all combination of extracts (Group 1-Group 8) with  
318 different comparisons were increased, and significantly different to control without extract ( $P > 0.05$ )  
319 in the 4<sup>th</sup> week after the challenge test. Only Group 2 was significantly different to others concoction  
320 extract (Figure 3). But the all concoction of extract (Group 1- Group 8) were significantly different  
321 to control (Group 9 and Group 10) without extract ( $P > 0.05$ ).

322



323

324 Figure 3. Lysozyme activity of tilapia in preventive method by using a concoction extract to  
 325 bacterial infection of *A. hydrophila* and *P. fluorescens* through injection and immersion  
 326 methods  
 327

328 The total bacteria of *A. hydrophila* and *P. fluorescens* in the body of tilapia in prevention  
 329 through injection (IP) and immersion methods were lower than controls (Group 9 and Group 10)  
 330 without extracts at the 4<sup>th</sup> week after the challenge test (IM) with pathogenic bacteria (Table 3). The  
 331 lowest bacterial density in tilapia was found for those fish given a combination extract of SF 50: ZZ  
 332 50 (Group 2) and different control with no extract/ Group 9 ( $P < 0.05$ ), as well as for the combined  
 333 extract of BP 90: SF 10 (Group 3), in which the total value of bacteria was lower than the control  
 334 (Group 9) and was significantly different ( $P < 0.05$ ). All concoction of extract (Group 1-Group 8)  
 335 caused total bacteria decreased in tilapia on week 4<sup>th</sup> after challenges with *A. hydrophila* and *P.*  
 336 *fluorescens* (IM). The decreased of total bacteria was significantly to the control (Group 9 and Group  
 337 10) with  $P < 0.05$ . The concoction SF 50 : ZZ 50 and BP 90 : SF 10 (Group 2 and Group 3) were  
 338 injection (IP) administration can suppress the bacterial growth in the fish body and significantly to the  
 339 others concoction. While, only the concoction SF 50 : ZZ 50 (Group 6) by immersion  
 340 administration was significantly with the others concoction and to the control/Group 10 ( $P < 0.05$ ).  
 341

342 Table 3. TPC of tilapia bacteria in preventive method by using combination of extracts to bacterial  
 343 infection of *A. hydrophila* and *P. fluorescens* through injection and immersion methods

Groups	Extracts	Total Bacteria ( $10^5$ CFU $mL^{-1}$ )
1	IP SF 60 : ZZ 40	$120 \pm 10^c$
2	IP SF 50 : ZZ 50	$32 \pm 5^b$
3	IP BP 90 : SF 10	$55 \pm 7^b$
4	IP BP 50 : SF 50	$117 \pm 11^c$
5	Immersion SF 60 : ZZ 40	$140 \pm 9^c$
6	Immersion SF 50 : ZZ 50	$45 \pm 5^b$
7	Immersion BP 90 : SF 10	$98 \pm 8^c$
8	Immersion BP 50 : SF 50	$110 \pm 10^c$

9	IP control	257±11 <sup>a</sup>
10	Immersion control	300±11 <sup>a</sup>

344 Notes: Values (means SD) with different superscript in a row show significant differences (P < 0.05)  
345

346 **Prevention against *A. hydrophila* and *P. fluorescens***

347 The highest percentage of SR and RPS of tilapia in preventive methods against *A. hydrophila*  
348 and *P. fluorescens* use were found on tilapia that had been given extracts SF 50:ZZ 50 (Group 2) and  
349 BP 90:SF 10 (Group 3) by injection until week 4. Meanwhile, the average SR of tilapia that were  
350 given a concoction of extract was demonstrated to be higher than controls/ Group 9 and Group 10  
351 (Table 4). The best SR and RPS of tilapia preventive using immersion method had given extracts SF  
352 50:ZZ 50 (Group 6) than others concoction (Groups 5, 7, 8) but, Groups 5, 7, and 8 were increase  
353 the SR and significantly different to the control (Group 10) with P<0.05.

354 Relative percent survival in all groups that administration with the concoction extracts were  
355 more than 65 %, only on Group 7 (Immersion BP 90 : SF 10) that lowest RPS (58%). Hardi et al  
356 (2018a), Ellis (1988), Osman *et al* (2009) says that RPS more than 60% showed the vaccine or  
357 immunostimulant were effective in protection bacteria infection.

358

359 Table 4. Survival Rate and RPS of tilapia bacteria in preventive method by using combination of  
360 extracts to bacterial infection of *A. hydrophila* and *P. fluorescens* through injection and  
361 immersion method

Groups	Extracts	SR	RPS
1	IP SF 60 : ZZ 40	88±10 <sup>b</sup>	83±10 <sup>b</sup>
2	IP SF 50 : ZZ 50	100±10 <sup>c</sup>	100±10 <sup>c</sup>
3	IP BP 90 : SF 10	100±10 <sup>c</sup>	100±10 <sup>c</sup>
4	IP BP 50 : SF 50	85±10 <sup>b</sup>	79±10 <sup>b</sup>
5	Immersion SF 60 : ZZ 40	75±10 <sup>b</sup>	65±10 <sup>b</sup>
6	Immersion SF 50 : ZZ 50	80±10 <sup>b</sup>	72±10 <sup>b</sup>
7	Immersion BP 90 : SF 10	70±10 <sup>b</sup>	58±10 <sup>b</sup>
8	Immersion BP 50 : SF 50	75±10 <sup>b</sup>	65±10 <sup>b</sup>
9	IP Control	29±10 <sup>a</sup>	
10	Immersion Control	29±10 <sup>a</sup>	

362 Notes: Values (means SD) with different superscript in a row show significant differences (P < 0.05)  
363

364 The use of immunostimulants and antibacterials derived from plant extracts has been  
365 previously carried out for fish and shrimp cultures for *Aeromonas salmonicida*, *A. hydrophila*, *Vibrio*  
366 *anguillarum*, *V. vulnificus*, *V. salmonicida*, *Yersinia ruckeri* and *Streptococcus* spp. (Barman *et al.*  
367 2013). According to Sakai (1999) and Findly & Munday (2002), immunostimulants are additional  
368 ingredients given to organisms and are able to increase the innate (non-specific) immune system to  
369 prevent pathogenic infections. Cells playing important roles in the non-specific immune system are

370 WBCs; their activity is influenced by fish, nutrition and the environment (Harrikrishnan *et al*, 2003;  
371 Mastan, 2015). The increase of WBCs of tilapia given all concoction extract (Group 1-8) was higher  
372 than the control without extract (Group 9 and 10), and the survival rate of tilapia after *A. hydrophila*  
373 and *P. fluorescens* infection reached 100% using a combination of SF 50: ZZ 50 and BP 90: SF 10  
374 through injection (Group 2 and Group 3). Immersion administration method, give a infection  
375 protection around 58-72%, and the best protection against bacteria shown in Group 6 (immersion SF  
376 50: ZZ 50) was 72%.

377 The difference methods in administration of extracts in fish affects on protection against  
378 bacteria infection. These results demonstrate that giving a combination of extracts can improve the  
379 non-spatial performance of the immune system of fish by producing more WBCs, subsequently  
380 inhibiting bacterial growth in the body (as can be seen in the lowest bacterial TPC data in this  
381 treatment compared to other combined extracts or control), and the different methods (IP and  
382 immersion) of administration show differences in performance of the immune system. Hardi et al  
383 (2019b) explain that the that the addition of combined extract into feed has a positive effect on the  
384 tilapia's immune system and the SF50/ZZ50 combination appears to improve the innate immune  
385 system of tilapia to treat and prevent bacterial infections through feed.

386 Based on Yin et al (2006), Jeney and Anderson (1993), and Mulero (1998) researchs, the  
387 administration of extract can be applied via injection, bathing or oral administration, the latter seems  
388 to be the most practicable in fish. Both injection and immersion methods have a different advantages  
389 and disadvantages (Evensen, 2016). Advantages the injection method are most potent, little waste of  
390 immunostimulant, Cost-effective method for high-value species. And the immersion method  
391 advantages are large-scale application possible, moderate stress to the fish, allows mass vaccination  
392 or immunostimulant of immunocompetent fish. Evensen (2016) explain about the disadvantages  
393 using immersion method than injection. Immersion method need a large amount of immunostimulant  
394 is needed, can be cost prohibitive, low to moderate efficacy and inferior to injection delivery in terms  
395 of efficacy Cost prohibitive for large fish. Based on research shows that the injection method can  
396 increase RPS rather than immersion at the same time. This is due to immunostimulant delivery in the  
397 body of the fish. The injection method, immunostimulant directly into the blood, while the immersion  
398 method, immunostimulant must penetrate the fish skin, so that more time is needed to improve the  
399 immune system, the same statement was explain by Midtlyng (2006).

400 The efficiency of method in immunostimulant administration in fish, can shown by RPS. The  
401 vaccine or immunostimulant potency and efficacy testing methods in fish and proposes detailed  
402 recommendation of test setup, challenge conditions and outcome acceptance criteria for controlled  
403 trials: exposure by bath challenge in two concentrations; maximum 10% non-specific mortality and  
404 20% within-group variation after challenge; control mortality  $\geq 60$  %, vaccinate mortality  $\leq 24$  %; and

405 following the Amend (1981) recommendations, the proposed acceptance criteria for potency equate  
406 to a standardised RPS of 60 % or above.

407 The total value of Tilapia RBCs in the preventive trial was higher than the control without  
408 extract, and significantly different ( $P < 0.05$ ). Both *A. hydrophila* and *P. fluorescens* bacteria produce  
409 hemolysin protein which can lyse RBCs, the numbers of which are therefore decreased in infected  
410 fish (Hardi *et al.* 2013). This decrease has also been noted to occur in tilapia infected with *S.*  
411 *agalactiae* (Hardi *et al.*, 2011), *S. iniae* (Sugiani *et al.* 2012), *A. hydrophila* (Dosim *et al.* 2006) and  
412 *Pseudomonas* sp. Tilapia being injected with extracellular and intracellular proteins from *A.*  
413 *hydrophila* (Hardi *et al.* 2013) and *Pseudomonas* sp. has been found to lead to degeneration, necrosis  
414 and bleeding in kidney organs, subsequently affecting fish blood production (Hardi *et al.* 2014).

415 However, similar observations were not observed for tilapia given combination of extracts  
416 (both methods administration), with RBC values being noted after infection. Hemoglobin (Hb) and  
417 hematocrit (Ht) values did not change in the first week with all treatments and the immersion or  
418 injection method administration including controls, and decreased values of Ht and Hb occurred in  
419 controls without extracts from 2<sup>nd</sup> and 4<sup>th</sup> weeks after injection and immersion application methods,  
420 whereas in the treatment fish given extract, Ht and Hb values were relatively increased but not  
421 significantly different between the difference in extract comparison.

422 The concentration decrease in RBC, Hb and Ht in tilapia that were not given extracts of *B.*  
423 *pandurata*, *S. ferox*, and *Z. zerumbet* with different concoctions in this study was due to bacterial  
424 infections of *A. hydrophila* and *P. fluorescens* (Hardi *et al.* 2013). According to Scott and Rogers  
425 (1981), Ht is the proportion of the volume of RBC in the blood. For a further explanation, the content  
426 of Hb in catfish has been found to decrease due to swelling of RBCs and the presence of poor Hb  
427 mobilization of the spleen and kidneys. Scott and Rogers (1981) noted that spleen disorders can cause  
428 an increase of Ht levels due to the introduction of erythrocytes into the circulatory system.

429 The total bacteria in the fish body were decrease in fish extract groups than control groups.  
430 flavonoids, alkaloid, and steroids are antibacterial substance or metabolic secunder, that have ability  
431 to inhibit the growth of bacteria. Extract of *B. pandurata* contains alkaloids, flavonoids and  
432 carbohydrates and *Z. zerumbet* contains alkaloids, flavonoids, steroids and carbohydrates, which are  
433 able to suppress the bacteria growth (Hardi *et al.*, 2016a) and Wink (2010). Ekstract of *S. ferox* has  
434 higher levels of alkaloids that play an important role as antibacterial properties (Hardi *et al.*, 2016a  
435 and Huang *et al.* 2008). Flavonoids and alkolooids could damage the wall surface of the bacteria that  
436 grow, particularly at low temperatures and fatty acids are believed to damage the structure and  
437 function of the bacterial cell wall and membrane (Hayes & Berkovitz 1979). This reseach showed  
438 that the extract improve the non specific immunity, supress the bacteria growth, and increase the  
439 bacterial infection protection.

440

441

## CONCLUSION

442

443

444

445

446

447

448

449

450

## ACKNOWLEDGEMENTS

451

452

453

454

455

456

457

## REFERENCES

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

This study demonstrates that a concoction of an extract with a ratio of SF 50: ZZ 50 and BP 10:SF 10 provides the best protection against *A. hydrophila* and *P. fluorescent* bacterial infections through injection and SF 50:ZZ 50 is the best ratio to protect the both bacteria infection in immersion methods. But, the injection is the better method to increase the innate (non-specific) immune system and protection againts *A. hydrophila* and *P. fluorescens* infection quickly than immersion. However, the concoction extracts ratio SF 50: ZZ 50 were increase immunity of non-specific tilapia and protect bacterial infection throught injection or immersion.

The author thanks the Ministry of Research and Technology of the Republic of Indonesia for funding this research through their national strategical research by institution in the 2018 fiscal year with contract number 121/UN17.41/KL/2018. The Study Program of Marine Culture, Faculty of Fisheries and Marine Science and the author also thanks The Marine and Fisheries Service of Kutai Kartanegara Regency, East Kalimantan for their support during the research.

- Amend DF. 1981. Potency testing of fish vaccines. *Developments in Biological Standardization*. 49:447–454.
- Anderson DP, Siwicki AK. 1995. Basic hematology and serology for fish health programs. Paper presented in second symposium on diseases in Asian Aquaculture “Aquatic Animal Health and the Environment”. Phuket, Thailand. 25 - 29 thOctober 1993. 17 hal
- Barman D, Nen P, Mandal SC, Kumar V. 2013. Immunostimulants for aquaculture health management. *Journal of Marine Science: Research and Development*. 3:134.
- Blaxhall PC, Daisley KW. 1973. Routine haematological methods for use with fish blood. *Journal Fish Biology*. 5: 577-581
- Bricknell I, Dalmo RA. 2005. The use of immunostimulants in fish larval aquaculture. *Fish Shellfish Immunol*. 19:457–72.
- Chowdhury MBR.1998. Involvement of Aeromonads and Pseudomonads in diseases of farmed fish in Bangladesh. *Fish Pathology* 33(4):247-254.
- Dosim, Hardi EH, Agustina. 2006. Efek penginjeksian produk intraseluler (ICP) dan ekstraseluler (ECP) bakteri *Pseudomonas* sp. terhadap gambaran darah ikan nila (*Oreochromis niloticus*). *Jurnal Ilmu Perikanan Tropis*. 19,1 :24-30.
- Ellis AE. 1988. *General principles of fish vaccination*. Academic Press, London.
- Evensen Ø. 2016. Development of fish vaccines: focusing on methods. In: Adams A (eds) *Fish Vaccines*. Birkhäuser Advances in Infectious Diseases. Springer, Basel. pp. 53-74.



- 477 Findlay VL, Munday BL. 2002. The immunomodulatory effects of levamisole on the nonspecific  
478 immune system of Atlantic salmon, *Salmo salar* L. *Journal of Fish Diseases*. 23:369–78.
- 479 Hardi EH, Pebrianto CA. 2012. Isolation and postulat koch test *Aeromonas* sp. and *Pseudomonas* sp.  
480 in tilapia (*Oreochromis niloticus*) in Loa Kulu aquaculture Kutai Kartanegara. *Jurnal Ilmu*  
481 *Perikanan Tropis*. 16:35-39. [in Indonesian]
- 482 Hardi EH, Pebrianto CA, Agustina. 2013. Histopatologi ikan nila (*Oreochromis niloticus*) asal Loa  
483 Kulu Kutai Kartanegara Kalimantan Timur yang diinjeksi produk ekstraselular (ECP) dan  
484 intraselular (ICP) bakteri *Aeromonas hydrophila*. *Konferensi Akuakultur Indonesia 2013*,  
485 Solo Jawa Tengah, Indonesia: 153-157.
- 486 Hardi EH, Pebrianto CA, Saptiani G. 2014. Toksisitas produk ekstraseluler dan intraseluler bakteri  
487 *Pseudomonas* sp. pada ikan nila (*Oreochromis niloticus*). *Jurnal Veteriner* 15,3:312-322.
- 488 Hardi EH, Kusuma IW, Suwinarti W, Agustina, Abbas I, Nugroho RA. 2016a. Antibacterial activities  
489 of some Borneo plant extracts against pathogenic bacteria of *Aeromonas hydrophila* and  
490 *Pseudomonas* sp. *AAFL Bioflux* 9(3):638-646.
- 491 Hardi E. H., Kusuma I. W., Suwinarti W., Agustina, Nugroho R. A., 2016b Antibacterial activity of  
492 *Boesenbergia pandurata*, *Zingiber zerumbet* and *Solanum ferox* extracts against *Aeromonas*  
493 *hydrophila* and *Pseudomonas* sp. *Nusantara Bioscience* 8(1):18- 21.
- 494 Hardi EH, Saptiani G, Kusuma IW, Suwinarti W, Nugroho RA. 2017. Immunomodulatory and  
495 antibacterial effects of *Boesenbergia pandurata*, *Solanum ferox*, and *Zingiber zerumbet* on  
496 tilapia, *Oreochromis niloticus*. *AAFL Bioflux* 10(2):182-190.
- 497 Hardi EH, Saptiani G, Nurkadina, Kusuma IW, Suwinarti W. 2018a. Uji in vitro gabungan ekstrak  
498 *Boesenbergia pandurata*, *Solanum ferox*, *Zingimber zerumbet* terhadap bakteri patogen pada  
499 ikan nila. *Jurnal Veteriner* 19 (1):35-44.
- 500 Hardi EH, SaptianiG, Kusuma IW, Suwinarti W, Sudaryono A. 2018b. Inhibition of fish bacteria  
501 pathogen in tilapia using a concoction three of Borneo plant extracts. *OP Conf. Ser.: Earth*  
502 *Environ. Sci.* 144: 012015 (pp 8).
- 503 Hardi EH, Nugroho RA, Kusuma IW, Suwinarti W, Apriza. 2019a. Immunomodulatory effect and  
504 disease resistance from of three Borneo plant extracts to *Aeromonas hydrophila* and  
505 *Pseudomonas fluorescens* in tilapia, *Oreochromis niloticus*. *Aquacultura Indonesiana*. 20 (1):  
506 41-47.
- 507 Hardi EH, Nugroho RA, Kusuma IW, Suwinarti W, Sudaryono A, Rostika R. 2019b. Borneo herbal  
508 plant extracts as a natural medication for prophylaxis and treatment of *Aeromonas hydrophila*  
509 and *Pseudomonas fluorescens* infection in tilapia (*Oreochromis niloticus*). *F1000Research*.  
510 7:1847 Last updated: 28 MAR 2019.
- 511 Harikrishnan R., Balasundaram C., 2008 In vitro and in vivo studies of the use of some medicinal  
512 herbals against the pathogen *Aeromonas hydrophila* in goldfish. *Journal of Aquatic Animal*  
513 *Health* 20:165-176.
- 514 Harikrishnan R, Balasundaram C, Kim MC, Kim JS, Han YJ, Heo MS. 2009. Innate immune response  
515 and disease resistance in *Carassius auratus* by triherbal solvent extracts. *Fish & Shellfish*  
516 *Immunology* 27:508–515.
- 517 Janda JM, Abbott SL. 2010. The genus *Aeromonas*: taxonomy, pathogenicity, and infection. *Clin*  
518 *Microbiol Rev.* 23:35–73.
- 519 Hayes ML, Berkovitz BKB. 1979 The reduction of fissure caries in Wistar rats by a soluble salt of  
520 nonanoic acid. *Archives of Oral Biology*. 24:663-666.

- 521 Huang W. H., Hsu C. W., Fang J. T., 2008 Central diabetes insipidus following digestion Solanum  
522 indicum L. concentrated solution. *Clinical Toxicology*. 46:293-296.
- 523 Jeney G, Anderson DP. 1993. Enhanced immune response and protection in rainbow trout to  
524 *Aeromonas salmonicida* bacterin following prior immersion in immunostimulants. *Fish*  
525 *Shellfish Immunology*. 3:51-8.
- 526 Lie O, Evensen O, Sorensen A, Froysada E. 1989. Study on lysozyme activity in some fish species.  
527 *Diseases of Aquatic Organism*. 6 : 1-5
- 528 Limsuwan S, Voravuthikunchai SP. 2008 *Boesenbergia pandurata* (Roxb.) Schltr., *Eleutherine*  
529 *americana* Merr. and *Rhodomlyrtus tomentosa* (Aiton) Hassk. as antibiofilm producing and  
530 antiquorum sensing in *Streptococcus pyogenes*. *FEMS Immunology and Medical*  
531 *Microbiology* 53:429-436.
- 532 Lygren B, Hamre K, Waagbo R. 1999. Effects of dietary pro and antioxidants on some protective  
533 mechanisms and health parameters in Atlantic Salmon. *Journal of Aquatic Animal Health*  
534 11(3):211-221
- 535 Karunasagar I, Rosalind G, Karunasagar J. 1991. Immunological response of the Indian major carps  
536 to *Aeromonas hydrophila* vaccine. *Journal Fish Diseases*. 14:413-7.
- 537 Mailoa MN, Tapotubun AM, Theodora EAA, Matruty. 2017. Analysis Total Plate Counte (TPC) on  
538 fresh steak tuna applications edible coating Caulerpa sp during stored at chilling temperature.  
539 IOP Conf. Series: Earth and Environmental Science 89:0012014 (pp 6)
- 540 Mastan SA. 2015. Use of Immunostimulants in aquaculture disease management. *International*  
541 *Journal of Fisheries and Aquatic Studies* 2015; 2(4): 277-280
- 542 Midtlyng PJ. 2016. Methods for Measuring Efficacy, Safety and Potency of Fish Vaccines. In: Adams  
543 A (eds) *Fish Vaccines*. Birkhäuser Advances in Infectious Diseases. Springer, Basel. pp. 119-  
544 141.
- 545 Monette S, Dallaire AD, Mingelbier M, Groman D, Uhland C, Richard JP, Paillard G, Johansson  
546 LM, Chivers DP, Ferguson HW, Leighton FA, Simko E. 2006. Massive mortality of common  
547 carp (*Cyprinus carpio*) in the St. Lawrence River in 2001: diagnostic investigation and  
548 experimental induction of lymphocytic encephalitis. *Veteriner Pathology*.43(3):302-10.
- 549 Osman KM, Mohamed LA, Rahman EHA, Soliman WS. 2009. Trials for Vaccination of Tilapia Fish  
550 Against *Aeromonas* and *Pseudomonas* Infections Using Monovalent, Bivalent and Polyvalent  
551 Vaccines. *World Journal of Fish and Marine Sciences*. 1 (4): 297-304.
- 552 Pridgeon JW, Klesius K. 2012. Major bacterial diseases in aquaculture and their vaccine  
553 development. *CAB Rev*. 7: 1-16.
- 554 Rodger HD. 2016. Fish Disease Causing Economic Impact in Global Aquaculture. A. Adams (ed.),  
555 *Fish Vaccines*, Birkhäuser Advances in Infectious Diseases, DOI 10.1007/978-3-0348-0980-  
556 1\_1
- 557 Sakai M. 1999. Current research status of fish immunostimulants. *Aquaculture* 172:63-92.
- 558 Scott AL, Rogers WA. 1981. Hematological effects of prolonged sublethal hypoxia on channel catfish  
559 *Ictalurus punctatus* (Rafinesque). *J Fish Biol*. 18:591-601.
- 560 Secombes CJ, Fletcher TC. 1992. The role of phagocytes in the protective mechanisms of fish. *Ann*  
561 *Rev Fish Dis*. 2: 58-71.
- 562 Sioutas S, Hoffmann RW, Pfeil-Putzien C, Fischer-Scherl T. 1991. Carp erythrodermatitis (CE) due  
563 to an *Aeromonas hydrophila* infection. Casuistic and experimental results. *Zentralb*  
564 *Veterinarmed B*. 38(3):186-94.

- 565 Sugiani D, Sukenda, Harris E, Lusiastuti AM. 2012. Haemato responses and histopathology of tilapia  
566 (*Oreochromis niloticus*) to co-infection *Streptococcus agalactiae* and *Aeromonas hydrophila*.  
567 J. Riset Akuakultur 85–91. [CrossRef]
- 568 Sumiati T, Sukenda, Nuryati S, Lusiastuti AM. 2015. Development of ELISA method to detect  
569 specific immune response in Nile tilapia (*O. niloticus*) vaccinated against *A. hydrophila* and  
570 *S. agalactiae*. J. Riset Akuakultur 10:243–250.
- 571 Wink M. 2010 Annual plant reviews volume 40: biochemistry of plant secondary metabolism. Second  
572 edition, Blackwell Publishing Ltd. USA, 445 pp.
- 573 Yin G, Jeney G, Racz T, Xu P, Jun X, Jeney Z. 2006. Effect of two Chinese herbs (*Astragalus radix*  
574 and *Scutellaria radix*) on non specific immune response of tilapia, *Oreochromis niloticus*.  
575 Aquaculture. 253:39–47.

ACCEPTED MANUSCRIPT